Clinical trials: Extramembranous Glomerulopathy
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Primary Membranous Nephropathy
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by…
- Trial name
- ALMOND (NCT05707377)
- Testing
- Zanubrutinib, Tacrolimus
- Where
- 45 sites in United States, Brazil and 7 more
- Volunteers
- 178 people
- Sponsor
- BeOne Medicines
Membranous Nephropathy
Adrenocorticotropic Hormone in Membranous Nephropathy
The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy.
- Trial name
- NCT03025828
- Testing
- ACTHar
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Glomerulonephritis, Membranous
Mycophenolate Mofetil in Membranous Nephropathy
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality.
- Trial name
- NCT00135967
- Testing
- mycophenolate mofetil orally 1000 mg twice a day (BID), prednisone 0,5 mg/kg orally on alternate days, intravenous (i.v.) methylprednisolone 1000 mg, total 9
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Membranous Nephropathy
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults.
- Trial name
- iRITUX (NCT06341205)
- Testing
- RiTUXimab Injection
- Where
- 14 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Chronic Stable Angina, Vascular Dementia
The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial
This study is designed as a bayesian basket trial , which aims to evaluate the efficacy of Danzhu Fuyuan Granule in patients with Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy
- Conditions
- Chronic Stable Angina, Vascular Dementia, Idiopathic Membranous Nephropathy
- Trial name
- NCT04498962
- Testing
- Danzhu Fuyuan Granule
- Where
- 7 sites in China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Jingqing Hu
Kidney Diseases, Chronic, Glomerular Diseases
Model Development and Application Based on Renal Pathology Images
This single-center retrospective observational cohort study will utilize digital renal pathology images along with corresponding clinical and laboratory data from patients who underwent kidney biopsy at Union Hospital, Tongji…
- Conditions
- Kidney Diseases, Chronic, Glomerular Diseases, Tubulointerstitial Kidney Diseases, IgA Nephropathy (IgAN)
- Trial name
- NCT07816874
- Where
- China
- Volunteers
- 8,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Membranous Nephropathy
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).
- Trial name
- NCT05810961
- Testing
- efgartigimod IV
- Where
- 31 sites in China
- Volunteers
- 8 people
- Sponsor
- argenx
Glomerulonephritis, Membranous, Diabetic Nephropathies
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Influence factors and preliminary mechanism of high incidence of thrombotic events in patients with idiopathic membranous nephropathy and diabetes kidney disease
- Conditions
- Glomerulonephritis, Membranous, Diabetic Nephropathies, Thrombelastography, Thromboembolism
- Trial name
- NCT05656963
- Testing
- Grouping based on previous laboratory results, no intervention.
- Where
- China
- Volunteers
- 741 people
- Sponsor
- Yipeng Liu
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Membranous Nephropathy
Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy
High-grade proteinuria is one of the key determinants of adverse renal prognosis in patients with primary membranous nephropathy (PMN).The main purpose of this study is to determine whether Rituximab combined with Cyclosporine is…
- Trial name
- NCT07861204
- Testing
- Rituximab combined with cyclosporine, rituximab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University First Hospital
Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced
Single-cell RNA Sequencing (scRNA-seq) to Investigate the Mechanisms Underlying the Induction of Regulatory T Cells in Patients With Extramembranous Glomerulonephritis Treated With Rituximab
Membranous nephropathy is a rare autoimmune kidney disease in which autoantibodies, most commonly anti-PLA2R1 antibodies, target podocyte antigens and may cause nephrotic syndrome.
- Conditions
- Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Nephrotic Syndrome
- Trial name
- TRANSCRIPT (NCT07811557)
- Testing
- Peripheral blood immune-cell profiling by single-cell RNA sequencing and in vitro pathway modulation assays
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)
QLS7305 injection is a chemically synthesized double-stranded small interfering RNA (siRNA) targeting complement C3, covalently linked to a ligand containing N-acetylgalactosamine (GalNAc) residues.
- Conditions
- IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G), Primary Membranous Nephropathy
- Trial name
- NCT07730632
- Testing
- QLS7305 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Idiopathic Membranous Nephropathy
Different Immunosuppressive Treatment in iMN
The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)
- Trial name
- NCT04745728
- Testing
- Prednisone, Cyclophosphamide, Rituximab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Glomerulonephritis, Membranous
Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy
The main clinical study will be a randomized, double-blind, placebo-controlled, long term study involving a 100 week treatment period.
- Trial name
- NCT01762852
- Testing
- Belimumab 10 mg
- Where
- 30 sites in United States, Australia and 8 more
- Sponsor
- GlaxoSmithKline
Hyperspectral Imaging, Idiopathic Membranous Nephropathy
Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN
Investigators propose hyperspectral imaging analysis as a method to distinguish the efficacy of hormone-combined cyclophosphamide therapy for PMN, and classify sensitive and insensitive patients treated with hormone-combined…
- Conditions
- Hyperspectral Imaging, Idiopathic Membranous Nephropathy, Cyclophosphamide
- Trial name
- NCT05850845
- Testing
- Microscopic hyperspectral imaging system
- Volunteers
- 40 people
- Sponsor
- Qianfoshan Hospital
Idiopathic Membranous Nephropathy
Study on the Therapeutic Effect of TCM Treatment for MDR MN
To evaluate the effectiveness and safety of the Chinese medicine treatment for multiple drug resistance of MN patients with Jianpiyiqi and Huoxuejiedu Recipe.
- Trial name
- NCT02610595
- Testing
- Jianpixiaozhong particles and Wuse Dietotherapy
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
IgA Nephropathy, Membranous Nephropathy
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
- Trial name
- NCT06690359
- Testing
- IM19 chimeric antigen receptor T cell injection
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)